2026
conference-abstract
OpenAlex
Kohei Shitara, Kensei Yamaguchi, Hirokazu Shoji, Jeeyun Lee et autres
4023 Background: Sone-Ve (AZD0901), an antibody-drug conjugate comprising an anti-CLDN18.2 antibody and monomethyl auristatin E, showed promising antitumor activity and a manageable safety profile in pts with advanced or metastatic gastric/GEJ cancers in the first-in-human study conducted in China. Methods: CLARITY-PanTumor01 is …
jp, kr, au, es, us, ca, nl, sg, br
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Do-Youn Oh, Yoon-Koo Kang, Kohei Shitara, Li-Tzong Chen et autres
4006 Background: Anti-PD-1 antibodies combined with chemotherapy (Chemo) are established as a standard first-line (1L) treatment for HER2-negative gastric/gastroesophageal (G/GEJ) cancer. Nivolumab (NIVO) and ipilimumab (IPI), an anti-CTLA-4 antibody, have complementary mechanisms of action on tumor immunity. Combining NIVO plus Chemo with …
kr, jp, tw
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Robin Lewis Jones, Neeta Somaiah, Sebastian Bauer, Michael C. Heinrich et autres
11501 Background: Most GISTs present with activating KIT mutations (exons 9/11) initially responsive to imatinib, but many progress due to diverse KIT resistance mutations (largely in exons 13/14/17/18). Velzatinib (subject to USAN approval), a novel selective KIT inhibitor, has broad mutation coverage …
gb, us, de, es, jp, cn, kr, fr
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
S Lim, Izuma Nakayama, Min-Hee Ryu, Jong Gwang Kim et autres
4007 Background: Anti-PD-1 antibodies combined with chemo are the standard 1L treatment for HER2-negative G/GEJ cancer. Prostaglandin E 2 (PGE 2 )-EP4 signaling is known to induce immunosuppressive tumor microenvironment, by inducing the differentiation of MDSCs and M2 macrophages, potentially contributing to …
kr, jp, tw
(code pays fourni par la source)